GSK Conducting PGx Trials for Newly Approved Tykerb; Monogram eTag Assays May Play Role | GenomeWeb
GlaxoSmithKline is hoping that pharmacogenomic studies of its newly approved targeted breast cancer drug Tykerb will help identify patients with other solid tumors likely to respond to the drug.
 
Separately, Monogram’s eTag dimerization assays may play a role in helping to identify these cohorts. Tykerb inhibits the tyrosine kinase components of the EGFR (ErbB1) and HER2 (ErbB2) receptors. Over-expression of these receptors is believed to reduce overall survival in cancer patients.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.